NVCR NovoCure Limited

14.66USD-2.07%Mkt Cap: 1.71B $P/E: —

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Fr…

Key Statistics

Company
Market Cap1.71B USD
Enterprise Value1.54B USD
Revenue (TTM)699.19M USD
Gross Profit488.47M USD
Net Income (TTM)-136.23M USD
Revenue/Share6.16 USD
Last Price14.66 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.6K
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-18.56
PEG—
EV/EBITDA-11.26
EV/Revenue2.20
P/S2.49
P/B5.15
EPS (TTM)-1.30
EPS (Forward)-0.81
52W Range
9.82042% of range21.45
52W High21.45 USD
52W Low9.820 USD
Profitability
Gross Margin74.54%
Oper. Margin-5.75%
EBITDA Margin-19.51%
Profit Margin-20.79%
ROE-40.01%
ROA-16.94%
Growth
Revenue Growth15.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-49.03M USD
CapEx (TTM)26.65M USD
FCF Margin3.26%
FCF Yield1.33%
Net Debt-207.14M USD
Net Debt/EBITDA1.52
Balance Sheet
Debt/Equity0.73
Current Ratio2.89
Quick Ratio2.66
Book Value/Sh2.90 USD
Cash/Share3.78 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)26.86 USD
Upside (mean)+83.2%
Target Range17.00 USD – 52.00 USD
17.00+83.2% to mean52.00
# Analysts7
Ownership
Shares Out.116.45M
Float96.42M
Insiders9.96%
Institutions90.64%
Short Interest
Short Ratio9.5d
Short % Float13.70%
Short % Out.10.13%
Shares Short11.80M
Short (prev mo.)9.17M
Technical
SMA 5016.60 (-11.7%)
SMA 20014.73 (-0.4%)
Beta0.99
S&P 52W Chg15.78%
Avg Vol (30d)1.34M
Avg Vol (10d)1.22M
Technical Indicators
RSI (14)35.4
MACD-0.4639
MACD Signal-0.3200
MACD Hist.-0.1440
BB Upper17.10 USD
BB Middle15.87 USD
BB Lower14.63 USD
BB Width15.55%
ATR (14)0.7563 USD
Vol Ratio (20d)2.49x